Cargando…
Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry
Implantation of biodegradable wafers impregnated with carmustine (BCNU) is one of the few chemotherapeutic modalities that have been evaluated in Phase III trials and approved by the US FDA for treatment of newly diagnosed high-grade glioma and recurrent glioblastoma. Enrolling up to 500 patients fo...
Autores principales: | Lillehei, Kevin O, Kalkanis, Steven N, Liau, Linda M, Mydland, Dellann Elliott, Olson, Jeffrey, Paleologos, Nina A, Ryken, Timothy, Johnson, Tania, Scullin, Evan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977275/ https://www.ncbi.nlm.nih.gov/pubmed/29206049 http://dx.doi.org/10.2217/cns-2017-0036 |
Ejemplares similares
-
Gliadel for brain metastasis
por: Abel, Taylor J., et al.
Publicado: (2013) -
Gliadel wafers in the treatment of malignant glioma: a systematic review
por: Perry, J., et al.
Publicado: (2007) -
Interstitial chemotherapy with biodegradable BCNU (Gliadel(®)) wafers in the treatment of malignant gliomas
por: Bota, Daniela A, et al.
Publicado: (2007) -
The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis
por: Xing, Wei-kang, et al.
Publicado: (2015) -
In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography
por: Doishita, Satoshi, et al.
Publicado: (2017)